Thursday - March 05, 2026

Category Archives: Science

Non-Alcoholic Steatohepatitis Clinical Trial Pipeline Expands as 70+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Non-Alcoholic Steatohepatitis (NASH) pipeline landscape. It covers the Non-Alcoholic Steatohepatitis pipeline drug profiles, including clinical and nonclinical stage products. It also … Continue reading →

Myelodysplastic Syndrome Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Myelodysplastic Syndrome Pipeline Insights 2026” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Living Forever – AI Accepted into NVIDIA Inception Program to Advance Interactive Family Legacy Platform

AI startup building interactive video avatars that preserve living people’s personalities, voices, and stories gains access to NVIDIA’s global AI ecosystem ATLANTA, GA – February 27, 2026 – Living Forever — AI, an Atlanta-based startup building fully interactive video AI digital … Continue reading →

Melanoma Treatment Pipeline Shows Strong Momentum as 150+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Melanoma Pipeline Insights 2026” report provides comprehensive insights about 150+ companies and 170+ pipeline drugs in the Melanoma Pipeline landscape. It covers the Melanoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Melanoma pipeline … Continue reading →

Major Depressive Disorder Clinical Trial Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Major Depressive Disorder Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Lou Gehrig’s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 75+ Key Companies | DelveInsight

DelveInsight’s “Lou Gehrig’s disease Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Lou Gehrig’s disease pipeline landscape. It covers the Lou Gehrig’s disease pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Liver Cancer Clinical Trial Pipeline Accelerates as 70+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Liver Cancer Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Liver Cancer pipeline landscape. It covers the Liver Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Influenza Clinical Trial Pipeline Gains Momentum: 120+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Influenza Pipeline Insight 2026” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Influenza pipeline landscape. It covers the Influenza Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Influenza Pipeline … Continue reading →

Safeguarding the Age of Generative AI: How Responsible Governance Is Becoming the New Tech Imperative

Generative artificial intelligence has rapidly evolved into one of the most influential technologies shaping modern communication, digital expression, and global information exchange. It now supports content creation, recommendation systems, creative tools, and automated decision making across a wide range of … Continue reading →